Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma
- PMID: 22553982
- PMCID: PMC3464963
- DOI: 10.1186/1748-717X-7-67
Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma
Abstract
Background: To report single-institutional clinical outcomes and toxicity with SBRT for cholangiocarcinoma.
Methods: From March 2009 to July 2011, 10 patients with 12 unresectable primary (n = 6) or recurrent (n = 6) cholangiocarcinoma lesions underwent abdominal SBRT. Sites treated included liver (n = 10), abdominal lymph nodes (n = 1), and adrenal gland (n = 1). SBRT was delivered in three (n = 2) or five (n = 10) consecutive daily fractions over one week. The median prescription dose was 55 Gy (range, 45-60). Treatment response was graded by RECIST v.1.1, and toxicities were scored by CTCAE v.4.0. Data was analyzed using the Kaplan-Meier method to determine rates of local control (LC), freedom from distant progression (FFDM) and overall survival (OS).
Results: The median follow-up was 14 months (range, 2-26 months). LC, defined as freedom from progression within the SBRT field, was 100%, but four patients treated to intrahepatic sites experienced progression elsewhere in the liver. Estimates for FFDM at 6 and 12 months were 73% and 31%, respectively. Sites of disease relapse included liver (n = 3), liver and lymph nodes (n = 1), liver and lungs (n = 1), lymph nodes (n = 1), and mesentery (n = 1). OS estimates for the cohort at 6 and 12 months were 83% and 73%, respectively. The most common Grade ≥ 2 early toxicities were Grade 2 nausea and vomiting (n = 5) and gastrointestinal pain (n = 2). Late ≥ 2 toxicities included Grade 2 gastrointestinal pain (n = 3), Grade 3 biliary stenosis (n = 1), and Grade 5 liver failure (n = 1).
Conclusions: SBRT shows promise as an effective local therapy for properly-selected patients with cholangiocarcinoma. Further follow-up is needed to better quantify the risk of late complications associated with SBRT.
Figures
Similar articles
-
Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.BMC Cancer. 2017 Nov 21;17(1):781. doi: 10.1186/s12885-017-3788-1. BMC Cancer. 2017. PMID: 29162055 Free PMC article.
-
Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.J Cancer Res Clin Oncol. 2020 Sep;146(9):2289-2297. doi: 10.1007/s00432-020-03285-9. Epub 2020 Jun 10. J Cancer Res Clin Oncol. 2020. PMID: 32524292
-
Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.Am J Clin Oncol. 2012 Dec;35(6):537-42. doi: 10.1097/COC.0b013e31821f876a. Am J Clin Oncol. 2012. PMID: 21659830
-
Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma.Clin Transl Oncol. 2023 Mar;25(3):731-738. doi: 10.1007/s12094-022-02979-5. Epub 2022 Nov 19. Clin Transl Oncol. 2023. PMID: 36401766 Review.
-
Stereotactic radiotherapy in the liver hilum. Basis for future studies.Strahlenther Onkol. 2012 Jan;188(1):35-41. doi: 10.1007/s00066-011-0002-2. Epub 2011 Dec 24. Strahlenther Onkol. 2012. PMID: 22194027 Review.
Cited by
-
Locoregional Therapy for Intrahepatic Cholangiocarcinoma.Cancers (Basel). 2023 Apr 20;15(8):2384. doi: 10.3390/cancers15082384. Cancers (Basel). 2023. PMID: 37190311 Free PMC article. Review.
-
Inter- and intrafraction dose variations in robotic stereotactic body radiation therapy (SBRT) for perihilar cholangiocarcinoma in the prospective phase I STRONG trial.Front Oncol. 2023 Mar 8;13:1114737. doi: 10.3389/fonc.2023.1114737. eCollection 2023. Front Oncol. 2023. PMID: 36969072 Free PMC article.
-
A phase II single arm study of Nivolumab with stereotactic Ablative radiation Therapy after induction chemotherapy in CHOlangiocarcinoma (NATCHO).BMC Cancer. 2022 Dec 12;22(1):1296. doi: 10.1186/s12885-022-10373-1. BMC Cancer. 2022. PMID: 36503610 Free PMC article. Clinical Trial.
-
Surgical resection versus transarterial chemoembolization followed by moderately hypofractionated radiotherapy in hepatocellular carcinoma.Strahlenther Onkol. 2023 Mar;199(3):293-303. doi: 10.1007/s00066-022-02022-0. Epub 2022 Nov 28. Strahlenther Onkol. 2023. PMID: 36441171
-
Clinical Efficacy of Hypofractionated Proton Beam Therapy for Intrahepatic Cholangiocarcinoma.Cancers (Basel). 2022 Nov 12;14(22):5561. doi: 10.3390/cancers14225561. Cancers (Basel). 2022. PMID: 36428654 Free PMC article.
References
-
- Jarnagin WR, Ruo L, Little SA. et al.Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98:1689–1700. - PubMed
-
- Ben-Josef E, Normolle D, Ensminger WD. et al.Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol. 2005;23:8739–8747. - PubMed
-
- Crane CH, Macdonald KO, Vauthey JN. et al.Limitations of conventional doses of chemoradiation for unresectable biliary cancer. Int J Radiat Oncol Biol Phys. 2002;53:969–974. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical